Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Satoshi MiyamotoHiddo J Lambers HeerspinkDick de ZeeuwMasao ToyodaDaisuke SuzukiTakashi HatanakaTohru NakamuraShinji KameiSatoshi MuraoKazuyuki HidaShinichiro AndoHiroaki AkaiYasushi TakahashiDaisuke KoyaMunehiro KitadaHisashi SuganoTomokazu NunoueAkihiko NakamuraMotofumi SasakiTatsuaki NakatouKei FujimotoDaiji KawanamiTakashi WadaNobuyuki MiyatakeMichihiro YoshidaKenichi Shikatanull nullPublished in: Diabetes, obesity & metabolism (2022)
The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria.